Trial Profile
Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects With Advanced Hepatocellular Carcinoma - A Phase II Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 24 Jul 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 26 Nov 2021 Planned End Date changed from 2 Apr 2022 to 31 Dec 2023.
- 26 Nov 2021 Planned primary completion date changed from 2 Apr 2021 to 31 Dec 2022.